AB50-ASA2-AA8,241,523146.615 (2g) Beginning in fiscal year 2025-26, from the appropriation under 24s. 20.435 (1) (fk), subject to sub. (3), the department shall distribute grants to
1hospitals, health systems, clinics, and educational entities that form health care 2education and training consortia for allied health professionals. The department 3shall distribute the grants under this subsection to hospitals, health systems, 4clinics, and educational entities that apply, in the form and manner determined by 5the department, to receive a grant. AB50-ASA2-AA8,241,126(2r) Beginning in fiscal year 2025-26, from the appropriation under s. 20.435 7(1) (fk), subject to sub. (3), the department shall distribute grants to hospitals, 8health systems, clinics, and educational entities that form health care education 9and training consortia for behavioral health providers. The department shall 10distribute the grants under this subsection to hospitals, health systems, clinics, and 11educational entities that apply, in the form and manner determined by the 12department, to receive a grant. AB50-ASA2-AA8,241,2115146.615 (3) (b) If the department distributes a grant to a hospital or clinic 16that has not previously received a grant under this section, the hospital or clinic 17receiving the grant may use the grant to create the education and infrastructure for 18training advanced practice clinicians or for activities authorized under par. (c). In 19distributing grants under this section, the department shall give preference to 20advanced practice clinician clinical training programs that include rural hospitals 21and rural clinics as clinical training locations. AB50-ASA2-AA8,242,223146.615 (3) (bm) Acceptable uses of grant moneys received under this section 24include reasonable expenses incurred by a trainee to fully succeed in training and
1eventual placement, expenses related to planning and implementing a training 2program, and up to $5,000 in equipment expenses. AB50-ASA2-AA8,242,116(1) Health care provider training grants. In the schedule under s. 20.005 7(3) for the appropriation to the department of health services under s. 20.435 (1) 8(fk), the dollar amount for fiscal year 2025-26 is adjusted to $3,500,000. In the 9schedule under s. 20.005 (3) for the appropriation to the department of health 10services under s. 20.435 (1) (cg), the dollar amount for fiscal year 2026-27 is 11adjusted to $3,500,000.”. AB50-ASA2-AA8,242,181449.45 (25d) Health-related social needs. The department shall request a 15waiver from the federal department of health and human services to provide 16reimbursement for services for health-related social needs under the Medical 17Assistance program. If the waiver is granted, the department shall provide 18reimbursement for services for health-related social needs under this subsection.”. AB50-ASA2-AA8,242,2120“Section 400. Subchapter IX of chapter 150 [precedes 150.99] of the statutes 21is created to read: AB50-ASA2-AA8,243,2
1SUBCHAPTER IX
2HEALTH CARE ENTITY OVERSIGHT AND TRANSPARENCY AB50-ASA2-AA8,243,44150.99 Definitions. In this subchapter: AB50-ASA2-AA8,243,105(1) “Acquisition” means the direct or indirect purchase, including lease, 6transfer, exchange, option, receipt of a conveyance, or creation of a joint venture, or 7any other manner of purchase, such as by a health care system, private equity 8group, hedge fund, publicly traded company, real estate investment trust, 9management services organization, insurance carrier, or any subsidiaries thereof, 10of a material amount of the assets or operations of a health care entity. AB50-ASA2-AA8,243,1111(2) “Affiliate” means any of the following: AB50-ASA2-AA8,243,1412(a) A person, entity, or organization that directly, indirectly, or through one or 13more intermediaries controls, is controlled by, or is under common control or 14ownership of another person, entity, or organization. AB50-ASA2-AA8,243,1815(b) A person whose business is operated under a lease, management, or 16operating agreement by another entity, or a person substantially all of whose 17property is operated under a management or operating agreement with that other 18entity. AB50-ASA2-AA8,243,2019(c) An entity that operates the business or substantially all the property of 20another entity under a lease, management, or operating agreement. AB50-ASA2-AA8,243,2321(d) Any out-of-state operations and corporate affiliates of an affiliate as 22defined in pars. (a) to (c), including significant equity investors, health care real 23estate investment trusts, or management services organizations. AB50-ASA2-AA8,244,424(3) “Arrangement” includes any agreement, association, partnership, joint
1venture, management services agreement, professional services agreement, health 2care staffing company agreement, or other arrangement that results in a change of 3governance or control of a health care entity or a department, subdivision, or 4subsidiary of a health care entity. AB50-ASA2-AA8,244,75(4) “Change of control” means an arrangement in which any person, 6corporation, partnership, or any entity acquires direct or indirect control over the 7operations of a health care entity in whole or in substantial part. AB50-ASA2-AA8,244,108(5) “Control,” “controlling,” “controlled by,” and “under common control 9with” means the direct or indirect power through ownership, contractual 10agreement, or otherwise to do any of the following: AB50-ASA2-AA8,244,1211(a) Vote 10 percent or more of any class of voting shares or interests of a health 12care entity. AB50-ASA2-AA8,244,1313(b) Direct the actions or policies of the specified entity. AB50-ASA2-AA8,244,2014(6) “Health care facility” means an institution that provides health care 15services or a health care setting, including hospitals and other inpatient facilities, 16health systems consisting of one or more health care entities that are jointly owned 17or managed, ambulatory surgical or treatment centers, skilled nursing facilities, 18residential treatment centers, diagnostic, laboratory, and imaging centers, 19freestanding emergency facilities, outpatient clinics, and rehabilitation and other 20therapeutic health settings. AB50-ASA2-AA8,244,2321(7) “Health care provider” means any person, corporation, partnership, 22governmental unit, state institution, medical practice, or other entity that performs 23or provides health care services to persons in the state. AB50-ASA2-AA8,245,224(8) “Health care services” means services and payments for the care,
1prevention, diagnosis, treatment, cure, or relief of a medical, dental, or behavioral 2health condition, illness, injury, or disease, including any of the following: AB50-ASA2-AA8,245,53(a) Inpatient, outpatient, habilitative, rehabilitative, dental, palliative, 4therapeutic, supportive, home health, or behavioral services provided by a health 5care entity. AB50-ASA2-AA8,245,76(b) Pharmacy, retail, and specialty, including any drug, device, or medical 7supply. AB50-ASA2-AA8,245,88(c) Performance of functions to refer, arrange, or coordinate care. AB50-ASA2-AA8,245,109(d) Equipment used such as durable medical equipment, diagnostic, surgical 10devices, or infusion. AB50-ASA2-AA8,245,1311(e) Technology associated with the provision of services or equipment in pars. 12(a) to (d) above, such as telehealth, electronic health records, software, claims 13processing, or utilization systems. AB50-ASA2-AA8,245,1914(9) “Health care staffing company” means a person, firm, corporation, 15partnership, or other business entity engaged in the business of providing or 16procuring, for temporary employment or contracting by a health care facility, any 17health care personnel, but does not include an individual who independently 18provides the individual’s own services on a temporary basis to health care facilities 19as an employee or contractor. AB50-ASA2-AA8,245,2220(10) “Licensee” means an individual who is licensed in the state as a 21physician, a doctor of osteopathy, or a physician assistant or a nurse practitioner 22who is authorized to diagnose and treat in the applicable clinical setting. AB50-ASA2-AA8,246,223(11) “Management services organization” means any organization or entity 24that contracts with a health care provider or provider organization to perform
1management or administrative services relating to, supporting, or facilitating the 2provision of health care services. AB50-ASA2-AA8,246,63(12) “Medical practice” means a corporate entity or partnership organized for 4the purpose of practicing medicine and permitted to practice medicine in the state, 5including partnerships, professional corporations, limited liability companies, and 6limited liability partnerships. AB50-ASA2-AA8,246,147(13) “Noncompetition agreement” means a written agreement between a 8licensee and another person under which the licensee agrees that the licensee, 9either alone or as an employee, associate, or affiliate of a third person, will not 10compete with the other person in providing products, processes, or services that are 11similar to the other person’s products, processes, or services for a period of time or 12within a specified geographic area after termination of employment or termination 13of a contract under which the licensee supplied goods to or performed services for 14the other person. AB50-ASA2-AA8,246,1915(14) “Nondisclosure agreement” means a written agreement under the terms 16of which a licensee must refrain from disclosing partially, fully, directly, or 17indirectly to any person, other than another party to the written agreement or to a 18person specified in the agreement as a 3rd-party beneficiary of the agreement, any 19of the following: AB50-ASA2-AA8,246,2420(a) A policy or practice that a party to the agreement required the licensee to 21use in patient care, other than individually identifiable health information that the 22licensee may not disclose under the Health Insurance Portability and 23Accountability Act of 1996, P.L. 104-191, in effect on the effective date of this 24paragraph .... [LRB inserts date]. AB50-ASA2-AA8,247,3
1(b) A policy, practice, or other information about or associated with the 2licensee’s employment, conditions of employment, or rate or amount of pay or other 3compensation. AB50-ASA2-AA8,247,94(c) Any other information the licensee possesses or to which the licensee has 5access by reason of the licensee’s employment by, or provision of services for or on 6behalf of, a party to the agreement, other than information that is subject to 7protection under applicable law as a trade secret of, or as otherwise proprietary to, 8another party to the agreement or to a person specified in the agreement as a third-9party beneficiary of the agreement. AB50-ASA2-AA8,247,1510(15) “Nondisparagement agreement” means a written agreement under 11which a licensee must refrain from making to a 3rd party a statement about 12another party to the agreement or about another person specified in the agreement 13as a 3rd-party beneficiary of the agreement, the effect of which causes or threatens 14to cause harm to the other party’s or person’s reputation, business relations, or 15other economic interests. AB50-ASA2-AA8,247,1616(16) “Ownership or investment interest” means any of the following: AB50-ASA2-AA8,247,1817(a) Direct or indirect possession of equity in the capital, stock, or profits 18totaling more than 5 percent of an entity. AB50-ASA2-AA8,247,2119(b) Interest held by an investor or group of investors who engages in the 20raising or returning of capital and who invests, develops, or disposes of specified 21assets. AB50-ASA2-AA8,248,222(c) Interest held by a pool of funds by investors, including a pool of funds 23managed or controlled by private limited partnerships, if those investors or the
1management of that pool or private limited partnership employ investment 2strategies of any kind to earn a return on that pool of funds. AB50-ASA2-AA8,248,63(17) “Private equity fund” means a publicly traded or nonpublicly traded 4company that collects capital investments from individuals or entities and 5purchases a direct or indirect ownership share or controlling interest of a health 6care entity. AB50-ASA2-AA8,248,157(18) “Provider organization” means any corporation, partnership, business 8trust, association, or organized group of persons that is in the business of health 9care delivery or management, whether incorporated or not, that represents one or 10more health care providers in contracting with insurance carriers for the payments 11of health care services. “Provider organization” includes physician organizations, 12physician-hospital organizations, independent practice associations, provider 13networks, accountable care organizations, management services organizations, and 14any other organization that contracts with insurance carriers for payment for 15health care services. AB50-ASA2-AA8,248,1616(19) “Significant equity investor” means any of the following: AB50-ASA2-AA8,248,1817(a) Any private equity fund with a direct or indirect ownership or investment 18interest in a health care entity. AB50-ASA2-AA8,248,2119(b) Any investor, group of investors, or other entity with a direct or indirect 20possession of equity in the capital, stock, or profits totaling more than 10 percent of 21a health care provider or provider organization. AB50-ASA2-AA8,249,222(c) Any private equity fund, investor, group of investors, or other entity with a 23direct or indirect controlling interest in a health care entity or that operates the
1business or substantially all of the property of a health care entity under a lease, 2management, or operating agreement. AB50-ASA2-AA8,249,94150.992 Material change transactions. (1) Notice. (a) Any health care 5entity shall, before consummating any material change transaction, submit written 6notice to the department not fewer than 180 days before the date of the proposed 7material change transaction. The department shall promulgate rules to define, for 8purposes of this subchapter, what entities are considered health care entities and 9what constitutes a material change transaction. AB50-ASA2-AA8,249,1410(b) Written notice shall include and contain the information the department 11determines is required. The health care entity may include any additional 12information supporting the written notice of the material change transaction. 13Notice is complete when the department determines that all required information 14has been received. AB50-ASA2-AA8,250,415(c) All information provided by the submitter as part of the notice shall be 16treated as public record unless the submitter designates documents or information 17as confidential when submitting the notice and the department concurs with the 18designation in accordance with a process specified by the department by rule. 19Information that is otherwise publicly available, or that has not been confidentially 20maintained by the source, shall be considered public. The department shall 21maintain the confidentiality of all confidential information obtained in relation to a 22material change transaction, except that the department may share confidential 23information with other appropriate state agencies and departments to carry out 24their respective authorities under this section and may disclose any information to
1an expert or consultant under contract with the department, provided that the 2expert or consultant is bound by the same confidentiality requirements as the 3department. The confidential information and documents may not be treated as 4public records and are not subject to inspection or copying under s. 19.35. AB50-ASA2-AA8,250,115(d) The department shall post on its publicly available website information 6about the material change transaction no less than 30 days before the anticipated 7implementation of the material change transaction or, if the department is notified 8less than 30 days before the anticipated implementation, as soon as is practicable. 9The department shall include in the information posted on its website under this 10paragraph at least all of the following information regarding the material change 11transaction: AB50-ASA2-AA8,250,13121. A summary of the proposed transaction, including the identity of the 13parties to the transaction. AB50-ASA2-AA8,250,15142. A description of the groups or individuals likely to be affected by the 15transaction. AB50-ASA2-AA8,250,18163. Information about services currently provided by the health care entity, 17commitments by the health care entity to continue such services, and any services 18that will be reduced or eliminated. AB50-ASA2-AA8,250,19194. Details about any public hearings and how to submit comments. AB50-ASA2-AA8,250,22205. Any other information from the notice and other materials submitted by the 21health care entity that the attorney general or the department determines would be 22in the public interest, except for materials designated confidential under par. (c). AB50-ASA2-AA8,251,223(e) For purposes of calculating time periods under this section, notice shall be
1considered received on the first business day after the department determines that 2notice is complete. AB50-ASA2-AA8,251,43(2) Preliminary review. (a) Within 30 days after receiving notice as 4described in sub. (1), the department shall do one of the following: AB50-ASA2-AA8,251,751. Approve the material change transaction and notify the health care entity 6in writing that a comprehensive review is not required for the material change 7transaction. AB50-ASA2-AA8,251,1082. Approve the material change transaction subject to conditions set by the 9department and notify the health care entity in writing of the conditions under 10which the transaction may be completed. AB50-ASA2-AA8,251,13113. Notify the health care entity in writing that the transaction is subject to a 12comprehensive review. The department may request additional information 13necessary to perform a comprehensive review under sub. (3). AB50-ASA2-AA8,251,1514(b) Nothing in this section limits or infringes upon the existing authority of 15any state agency or the attorney general to review any transactions. AB50-ASA2-AA8,251,1916(3) Comprehensive review process. (a) For purposes of this subsection, 17“market power” means possessing 30 percent or more market share in any line of 18service in the relevant geographic area or meeting other criteria that the 19department may define by rule. AB50-ASA2-AA8,251,2120(b) A comprehensive review is required when any of the following apply to the 21material change transaction: AB50-ASA2-AA8,251,23221. The transaction will result in the transfer of assets valued above $20 23million. AB50-ASA2-AA8,252,2
12. The transaction occurs in a highly consolidated market for any line of 2services offered by any party to the material change transaction. AB50-ASA2-AA8,252,433. The transaction will cause a significant change in market share such that 4any resulting health care entity possesses market power upon completion. AB50-ASA2-AA8,252,754. The transaction will otherwise reduce competition, including effects of 6vertical or cross-market transactions among different product or geographic 7markets. AB50-ASA2-AA8,252,985. Either party to the material change transaction possesses market power 9prior to the transaction. AB50-ASA2-AA8,252,12106. The department, at its sole discretion, determines that the material change 11transaction is likely to have a material impact on the cost of, quality of, equity of, or 12access to health care services in any region in the state. AB50-ASA2-AA8,252,1713(c) No later than 90 days after determining a material change transaction is 14subject to a comprehensive review, the department shall conduct the review and 15shall conduct one or more public hearings or public meetings, one of which shall be 16in the county in which the health care entity is located, to hear comments from 17interested parties. AB50-ASA2-AA8,253,218(d) Not more than 90 days after determining that the material change 19transaction is subject to a comprehensive review under this subsection, the 20department shall produce a cost and market impact review report containing the 21findings and conclusions of the cost and market impact review, provided that the 22health care entity has complied with the requests for information or documents 23pursuant to this subsection within 21 days of the request or by a later date set by 24mutual agreement of the health care entity and the department. The cost and
1market impact review report shall be posted publicly and may not disclose 2confidential information. AB50-ASA2-AA8,253,53(e) The cost and market impact review may examine factors relating to the 4proposed material change transaction, transacting parties, and their relative 5market position, including any of the following: AB50-ASA2-AA8,253,761. The market share of each transacting party and the likely effects of the 7material change transaction on competition. AB50-ASA2-AA8,253,1082. Any previous material change transaction involving any transacting party, 9including acquisitions or mergers of similar health care providers, whether or not in 10the same state. AB50-ASA2-AA8,253,13113. The prices charged by each transacting party for services, including their 12relative prices compared to others’ prices for the same services in the same 13geographic area.
/2025/related/amendments/ab50/aa8_asa2_ab50
true
amends
/2025/related/amendments/ab50/aa8_asa2_ab50/401/_11
amends/2025/REG/AB50-ASA2-AA8,244,12
amends/2025/REG/AB50-ASA2-AA8,244,12
section
true